Disease Attributes  >>  Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
NCT02345161: A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
3
1811
Europe, RoW
Triple FF/UMEC/VI, Placebo to match FF/UMEC/VI, Budesonide/Formoterol, Placebo to match Budesonide/Formoterol combination, Albuterol/salbutamol
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
04/16
04/16
NCT02731846: A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Withdrawn
3
0
Canada, Europe
Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg, Fluticasone furoate 100 mcg + Vilanterol 25 mcg, Umeclidinium 62.5 mcg, Placebo ELLIPTA inhaler, Albuterol/Salbutamol
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
11/16
11/16
IMPACT, NCT02164513: A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Completed
3
10355
Europe, Canada, Japan, US, RoW
fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)
GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
07/17
07/17

Download Options